June 26, 2024
1 min read

India’s Pharma to Hit Rs 5.5 Trillion

The report showed that currently the market is valued at Rs 2 trillion, with a growth rate of 11 per cent over the last 20 years….reports Asian Lite News

India’s Domestic Pharma Formulations (DomForm) market, which includes branded generic medicines, is expected to more than double and cross Rs 5.5 trillion in the next 10 years at a CAGR of 10 per cent, according to a new report.

The report, by investment banking firm Avendus Capital, showed that currently the market is valued at Rs 2 trillion, with a growth rate of 11 per cent over the last 20 years.

However, with a gradual transition from a primarily doctor-branded prescription model, more stringent quality compliance, and government policies and regulatory measures, the market is expected to make a significant growth.

“We are encouraged by the government of India’s Pharma Vision 2047, which is aimed at making medicines more equitable, accessible, and affordable while ensuring high quality and more sustainable manufacturing practices. We believe that the sector will more than double from today, comfortably crossing about Rs 5.5 trillion in value by 2034,” the report said.

The report also predicted shifts in channel volumes, with trade generics and the unbranded “Generic Generics”, including Jan Aushadhi centres and government hospital procurement, gaining more traction.

“We estimate that the DomForm market will continue growing at 9-10 per cent CAGR in the next 10 years. With the expansion of trade generics and Jan Aushadhi channels, we expect about 30 per cent volume contribution from these in 10 years,” the report said.

Although off-patent generics currently account for nearly 100 per cent of the market, because of local manufacturing and process innovations, the prices of medicines are significantly lower than the global average.

Currently, more than 3,000 companies and almost 10,000 manufacturing units exist, yet they come with significant variations in quality standards.

Substandard, spurious and counterfeit drugs account for a staggering 20 per cent of the market, as per official testing.

ALSO READ: India’s Capex Fuels Capital Goods Surge

Previous Story

India’s Wedding Market Now $130 Billion

Next Story

Farakka treaty: Centre denies claim of not consulting Bengal

Latest from Business

PM Modi: India poised to lead next tech wave

PM Modi underscored that the country is poised to lead the next wave of digital transformation in 5G…reports Asian Lite News Prime Minister Narendra Modi on Wednesday hailed India’s progress in expanding

India Hits 100GW Solar

The expansion is not only in scale but also in quality, with significant capacity dedicated to high-efficiency modules. Many manufacturers have adopted vertically integrated operations, enhancing quality, reducing costs, and improving resilience

Jewellery Exports Shine Bright

The GJEPC noted that product diversification has played a major role in sustaining momentum. Lightweight and contemporary designs are gaining traction among younger global consumers, helping Indian jewellers appeal to a wider

China Curbs Hit India’s Electronics Boom

The ICEA noted this results in delays, inefficiencies, and higher costs — alternatives from Japan or Korea cost up to four times more than Chinese machinery. India’s transformation into a global electronics
Go toTop

Don't Miss

Tough battle awaits Harsimrat Badal in Bathinda

The Akali Dal had contested the 2022 assembly elections in

With eye on Gulf, India to host World Spice Congress

The 14th edition of World Spice Congress (WSC) is to